Related references
Note: Only part of the references are listed.Recent Developments in the Medical and Surgical Treatment of Melanoma
Vita Saranga-Perry et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Cancer Treatment and Survivorship Statistics, 2014
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma
David McDermott et al.
CANCER TREATMENT REVIEWS (2014)
Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies
S. Jang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
The use of endogenous T cells for adoptive transfer
Cassian Yee
IMMUNOLOGICAL REVIEWS (2014)
Exploiting the curative potential of adoptive T-cell therapy for cancer
Christian S. Hinrichs et al.
IMMUNOLOGICAL REVIEWS (2014)
At the Bedside: Adoptive cell therapy for melanoma-clinical development
Jeffrey S. Weber
JOURNAL OF LEUKOCYTE BIOLOGY (2014)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Dmitriy Zamarin et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma
Howard L. Kaufman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Mutations of the BRAF gene in human cancer, by Davies etal. (Nature 2002; 417: 94954)
G. W. M. Millington
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2013)
Combination chemotherapy of carboplatin and paclitaxel for metastatic melanoma
Yuki Sato et al.
JOURNAL OF DERMATOLOGY (2013)
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
Howard L. Kaufman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy
Christel Devaud et al.
ONCOIMMUNOLOGY (2013)
Surgery for Distant Metastatic Melanoma Improves Survival
Bin B. R. Kroon
ANNALS OF SURGICAL ONCOLOGY (2012)
Surgical Management of Melanoma Lung Metastasis: An Analysis of Survival Outcomes in 292 Consecutive Patients
Terence C. Chua et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer
T. T. Sahin et al.
CANCER GENE THERAPY (2012)
Systemic Combination Virotherapy for Melanoma with Tumor Antigen-Expressing Vesicular Stomatitis Virus and Adoptive T-cell Transfer
Diana M. Rommelfanger et al.
CANCER RESEARCH (2012)
Newcastle disease virus: A promising agent for tumour immunotherapy
Lixiang Zhao et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2012)
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
James S. Wilmott et al.
CLINICAL CANCER RESEARCH (2012)
Fusogenic Oncolytic Herpes Simplex Viruses as a Potent and Personalized Cancer Vaccine
Qi-Xiang Li et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Phase II Trial of Intravenous Administration of Reolysin® (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma
Evanthia Galanis et al.
MOLECULAR THERAPY (2012)
Oncolytic virotherapy
Stephen J. Russell et al.
NATURE BIOTECHNOLOGY (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Rationale for Complete Metastasectomy in Patients With Stage IV Metastatic Melanoma
David W. Ollila et al.
JOURNAL OF SURGICAL ONCOLOGY (2011)
A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma
Tae-Ho Hwang et al.
MOLECULAR THERAPY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Epigenetic Silencing of IRF7 and/or IRF5 in Lung Cancer Cells Leads to Increased Sensitivity to Oncolytic Viruses
Qunfang Li et al.
PLOS ONE (2011)
Years of Potential Life Lost and Indirect Costs of Melanoma and Non-Melanoma Skin Cancer A Systematic Review of the Literature
Gery P. Guy et al.
PHARMACOECONOMICS (2011)
Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
Howard L. Kaufman et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Oncogenic Ras Promotes Reovirus Spread by Suppressing IFN-β Production through Negative Regulation of RIG-I Signaling
Maya Shmulevitz et al.
CANCER RESEARCH (2010)
OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma
Howard L. Kaufman et al.
FUTURE ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
Neil N. Senzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Completely Regressed Cutaneous Melanocytic Lesion Revisited
Timothy W. McCardle et al.
SEMINARS IN ONCOLOGY (2009)
Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10
Daisuke Watanabe et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2008)
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
Jennifer C. C. Hu et al.
CLINICAL CANCER RESEARCH (2006)
Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer
Hideto Kimata et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors
HL Kaufman et al.
HUMAN GENE THERAPY (2006)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma
HL Kaufman et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus A21
DR Shafren et al.
CLINICAL CANCER RESEARCH (2004)
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology group
HL Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
BL Liu et al.
GENE THERAPY (2003)
The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to consider
R Vile et al.
CANCER GENE THERAPY (2002)
Oncolytic herpes simplex virus vectors for cancer virotherapy
S Varghese et al.
CANCER GENE THERAPY (2002)
Clinical infection control in gene therapy: A multidisciplinary conference
ME Evans et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2000)
Share Paper
